Pursuant to Reg. 30 & 33 of the SEBI (LODR) Regulations, 2015, please find enclosed herewith the following: 1. Unaudited FR (Standalone & Consolidated) for the Quarter & Nine Months ended ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 16.8 pts less than Nifty Microcap 250 and 17.5 pts less than its Medical Equipment & Supplies peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Shree Pacetronix Ltd reported its Q3 FY26 results with standalone revenue from operations of ₹433.46 lakhs, up about 19.6% from ₹362.51 lakhs in Q3 FY25, and a profit after tax of ₹6.11 lakhs versus a loss of ₹11.44 lakhs a year ago. For the nine months ended December 2025, standalone revenue grew around 30% to ₹1,626.95 lakhs (from ₹1,252.33 lakhs), while PAT jumped sharply to ₹204.69 lakhs from ₹28.75 lakhs, translating to an EPS of ₹5.67. The auditor S. R. Naredi & Co. issued an unmodified (clean) limited review opinion on both standalone and consolidated results. During the quarter, the company allotted 2,25,450 convertible warrants to promoter group entities at ₹81 per warrant, aggregating to about ₹1.83 crore, with 25% paid upfront. Consolidated results are largely in line with standalone, with subsidiary Shree Coratomic Limited contributing negligible revenue and a small loss.
Strong nine-month revenue growth of ~30% and a more than 6x jump in profits signal a sharp turnaround for shareholders, though the much weaker Q3 sequential performance (PAT falling from ₹131.58 lakhs in Q2 to just ₹6.11 lakhs) may temper excitement. The preferential warrant allotment to promoters at ₹81 could be a positive signal of insider confidence, but it also means potential equity dilution over the next 18 months.